Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

NCT07537400 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
10
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Shaare Zedek Medical Center

Collaborators